Andreas Argyrides Analyst PerformanceManaging Director, Senior Biotech Analyst at OppenheimerAndreas Argyrides is a stock analyst at Oppenheimer focused in the medical sector, covering 24 publicly traded companies. Over the past year, Andreas Argyrides has issued 30 stock ratings, including buy, hold, and sell recommendations. While full access to Andreas Argyrides' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andreas Argyrides' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings41 Last 3 YearsBuy Recommendations77.50% 31 Buy RatingsCompanies Covered24 Unique Companies Ratings Distribution40RatingsDistribution of strong buy, buy, hold, and sell ratings by Andreas Argyrides.RatingPercentageCount Strong Buy0.0%0 ratings Buy77.5%31 ratings Hold17.5%7 ratings Sell5.0%2 ratingsOut of 40 total stock ratings issued by Andreas Argyrides at Oppenheimer, the majority (77.5%) have been Buy recommendations, followed by 17.5% Hold and 5.0% Sell.Best & Worst CallsBest Call0000.0%CNTAMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%KRROMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ95.8% of companies on NASDAQ23 companiesNYSE4.2% of companies on NYSE1 companyAndreas Argyrides, an analyst at Oppenheimer, currently covers 24 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical23 companies95.8%Manufacturing1 company4.2%Andreas Argyrides of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE16 companies66.7%MED - DRUGS7 companies29.2%Miscellaneous1 company4.2% About Andreas ArgyridesAndreas Argyrides is an Executive Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Andreas was Vice President and Senior Analyst covering Biotechnology at Wedbush. Prior to Wedbush, Andreas spent a decade in various roles across the healthcare industry including as healthcare sector specialist and research analyst at a long/short biotech focused hedge fund. Andreas received his BA in History and Economics with honors from New York University.Follow on LinkedIn Andreas Argyrides' Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIRDOpus Genetics3/16/2026Initiated Coverage$5.03$10.00Outperform$0.0000.00% ROILQDALiquidia3/12/2026Boost Price Target$37.07$19.00Underperform$0.0000.00% ROIGOSSGossamer Bio3/5/2026Lower Price Target$0.48$3.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics2/26/2026Boost Price Target$500.08$600.00Outperform$0.0000.00% ROIMLTXMoonLake Immunotherapeutics2/24/2026Boost Price Target$18.68$35.00Outperform$0.0000.00% ROIEVMNEvommune1/22/2026Initiated Coverage$18.64$42.00Outperform$0.0000.00% ROISVRASavara12/23/2025Set Price Target$6.51$10.00$0.0000.00% ROIDYNDyne Therapeutics12/10/2025Upgrade$18.44$40.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences11/24/2025Reiterated Rating$34.31$62.00Outperform$0.0000.00% ROISVRASavara11/14/2025Boost Price Target$4.33$9.00Outperform$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. DYNDyne Therapeutics11/12/2025Lower Price Target$18.86$11.00Market Perform$0.0000.00% ROIKROSKeros Therapeutics11/12/2025Reiterated Rating$17.28$27.00Outperform$0.0000.00% ROIDYNDyne Therapeutics10/10/2025Reiterated Rating$14.68$13.00Market Perform$0.0000.00% ROIDYNDyne Therapeutics10/10/2025Downgrade$14.68$13.00Market Perform$0.0000.00% ROIMNPRMonopar Therapeutics10/2/2025Set Price Target$92.52$115.00Outperform$0.0000.00% ROILRMRLarimar Therapeutics10/2/2025Lower Price Target$4.46$21.00Outperform$0.0000.00% ROIBNTCBenitec Biopharma9/16/2025Reiterated Rating$13.60$29.00Outperform$0.0000.00% ROIKALAKALA BIO9/11/2025Boost Price Target$795.75$1,650.00Outperform$0.0000.00% ROISVRASavara9/8/2025Boost Price Target$3.72$8.00Outperform$0.0000.00% ROIUTHRUnited Therapeutics9/5/2025Boost Price Target$387.63$575.00Outperform$0.0000.00% ROIMNKDMannKind9/5/2025Boost Price Target$5.54$15.00Outperform$0.0000.00% ROIMNPRMonopar Therapeutics9/3/2025Initiated Coverage$33.93$77.00Outperform$0.0000.00% ROIABEOAbeona Therapeutics8/15/2025Boost Price Target$7.25$20.00Outperform$0.0000.00% ROIDYNDyne Therapeutics8/6/2025Lower Price Target$10.47$13.00Outperform$0.0000.00% ROIHRMYHarmony Biosciences6/2/2025Initiated Coverage$34.69$61.00Outperform$0.0000.00% ROIDYNDyne Therapeutics6/2/2025Initiated Coverage$12.04$34.00Outperform$0.0000.00% ROIAQSTAquestive Therapeutics6/2/2025Initiated Coverage$2.71$7.00Outperform$0.0000.00% ROIABEOAbeona Therapeutics6/2/2025Initiated Coverage$6.29$19.00Outperform$0.0000.00% ROIKALAKALA BIO6/2/2025Reiterated Rating$183.80$750.00Outperform$0.0000.00% ROIIFRXInflaRx5/29/2025Lower Price Target$0.83$3.00Outperform$0.0000.00% ROILQDALiquidia5/19/2025Set Price Target$18.88$13.00Underperform$00.0000.00% ROIRANIRani Therapeutics5/16/2025Lower Price Target$0.73$4.00Outperform$0.0000.00% ROIKRROKorro Bio5/13/2025Lower Price Target$16.11$90.00Outperform$00.0000.00% ROIPRQRProQR Therapeutics5/13/2025Lower Price Target$1.59$9.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals5/8/2025Initiated Coverage$12.41$6.00Outperform$00.0000.00% ROIIFRXInflaRx5/8/2025Initiated Coverage$1.47$6.00Outperform$0.0000.00% ROIKROSKeros Therapeutics1/16/2025Lower Price Target$10.19$23.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
